Serina Therapeutics Inc (SER)

$1.90 +0.02 (1.06%)
Market Cap 28.20M
Revenue (ttm) 130,000.00
Net Income (ttm) -19.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14,753.85%
Debt to Equity Ratio 0.17
Volume 60,700
Avg Vol 153,686
Day's Range N/A - N/A
Shares Out 15.00M
Stochastic %K 69%
Beta 1.15
Analysts Strong Sell
Price Target $13.00

Company Profile

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has c...

Industry: Biotechnology
Sector: Healthcare
Phone: 256 327 9630
Address:
601 Genome Way, Suite 2001, Huntsville, United States
robiein35
robiein35 Jun. 1 at 11:40 PM
$SER Accumulate and hold for 6 months for + or - 100%. Serina expects to advance to the next cohort following a blinded safety review in the third quarter of 2026, with topline data from the study anticipated in the first half of 2027.
1 · Reply
gamgee11
gamgee11 May. 24 at 5:52 PM
$SER
0 · Reply
dthekang
dthekang May. 22 at 3:12 PM
$SER anyone?
0 · Reply
dthekang
dthekang May. 20 at 9:51 AM
$SER anybody here?
0 · Reply
dthekang
dthekang May. 14 at 2:05 PM
$SER cmon…
0 · Reply
SuperGreenToday
SuperGreenToday May. 12 at 12:44 PM
$SER
0 · Reply
MauriceMauriceMaurice
MauriceMauriceMaurice May. 11 at 10:24 PM
$SMMT $EGG $SER
0 · Reply
Monogg
Monogg May. 5 at 10:35 PM
$SER These are scammers—they’ve approved another dilution up to 2 million shares, with the first step being 125,000. Be careful! Do not buy shares of these fraudsters.
0 · Reply
dthekang
dthekang May. 4 at 6:53 PM
$SER
0 · Reply
gmc109
gmc109 Apr. 27 at 4:15 PM
$SER in few days to 4$?
0 · Reply
Latest News on SER
Serina Therapeutics files to sell 16.45M shares of common stock for holders

2026-05-22T20:06:20.000Z - 17 days ago

Serina Therapeutics files to sell 16.45M shares of common stock for holders

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

May 14, 2026, 4:20 PM EDT - 25 days ago

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

Apr 7, 2026, 6:00 AM EDT - 2 months ago

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

Serina Therapeutics announces NYSE acceptance of plan to regain compliance

2026-04-02T20:21:42.000Z - 2 months ago

Serina Therapeutics announces NYSE acceptance of plan to regain compliance

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

Apr 2, 2026, 4:13 PM EDT - 2 months ago

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

Serina Therapeutics to Present at the 38th Annual Roth Conference

Mar 24, 2026, 6:00 AM EDT - 2 months ago

Serina Therapeutics to Present at the 38th Annual Roth Conference

Serina Therapeutics names Greg Bailey co-chairman

2026-03-18T20:30:41.000Z - 2 months ago

Serina Therapeutics names Greg Bailey co-chairman

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

Mar 18, 2026, 4:10 PM EDT - 2 months ago

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics doses first patient in SER-252 trial

2026-02-24T21:37:35.000Z - 3 months ago

Serina Therapeutics doses first patient in SER-252 trial

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Feb 24, 2026, 4:05 PM EST - 3 months ago

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics says first patient enrolled in Phase 1b trial of SER-252

2026-02-19T11:20:45.000Z - 3 months ago

Serina Therapeutics says first patient enrolled in Phase 1b trial of SER-252

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Feb 19, 2026, 6:00 AM EST - 3 months ago

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event

Feb 3, 2026, 6:00 AM EST - 4 months ago

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event

Serina Therapeutics files to sell 7.72M shares of common stock for holders

2026-01-30T22:25:13.000Z - 4 months ago

Serina Therapeutics files to sell 7.72M shares of common stock for holders

This Is Why Serina Therapeutics Stock (SER) Rocketed Today

2026-01-29T14:53:03.000Z - 4 months ago

This Is Why Serina Therapeutics Stock (SER) Rocketed Today

Serina Therapeutics announces FDA clearance of SER-252 new drug application

2026-01-28T21:31:30.000Z - 4 months ago

Serina Therapeutics announces FDA clearance of SER-252 new drug application

Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease

Jan 28, 2026, 4:12 PM EST - 4 months ago

Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease

Serina Therapeutics receives NYSE deficiency notice on equity standards

2026-01-15T21:40:23.000Z - 5 months ago

Serina Therapeutics receives NYSE deficiency notice on equity standards

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

Jan 15, 2026, 4:30 PM EST - 5 months ago

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

Dec 11, 2025, 4:15 PM EST - 6 months ago

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

Serina Therapeutics submits complete response to FDA clinical hold letter

2025-12-10T21:45:32.000Z - 6 months ago

Serina Therapeutics submits complete response to FDA clinical hold letter

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Dec 10, 2025, 4:30 PM EST - 6 months ago

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Serina Therapeutics reports Q3 EPS (45c) vs. 13c last year

2025-11-13T11:15:52.000Z - 7 months ago

Serina Therapeutics reports Q3 EPS (45c) vs. 13c last year

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 13, 2025, 6:10 AM EST - 7 months ago

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Serina Therapeutics says FDA places clinical hold on IND for SER-252

2025-11-03T11:16:17.000Z - 7 months ago

Serina Therapeutics says FDA places clinical hold on IND for SER-252

Serina Therapeutics Provides Regulatory Update on SER-252 Program

Nov 3, 2025, 6:05 AM EST - 7 months ago

Serina Therapeutics Provides Regulatory Update on SER-252 Program

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

Oct 8, 2025, 11:00 AM EDT - 8 months ago

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease

Oct 6, 2025, 4:15 PM EDT - 8 months ago

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease

Serina Therapeutics Inc trading resumes

2025-09-09T20:00:41.000Z - 9 months ago

Serina Therapeutics Inc trading resumes

Serina Therapeutics announces agreement to access up to $20M in financing

2025-09-09T19:30:14.000Z - 9 months ago

Serina Therapeutics announces agreement to access up to $20M in financing

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease

Sep 9, 2025, 3:20 PM EDT - 9 months ago

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease

Serina Therapeutics Inc trading halted, news pending

2025-09-09T19:15:24.000Z - 9 months ago

Serina Therapeutics Inc trading halted, news pending

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 6:00 AM EDT - 9 months ago

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Serina Therapeutics Stock (SER) Soars 20% on FDA Support

2025-08-27T01:27:00.000Z - 10 months ago

Serina Therapeutics Stock (SER) Soars 20% on FDA Support

Serina Therapeutics Inc trading resumes

2025-08-26T13:45:11.000Z - 10 months ago

Serina Therapeutics Inc trading resumes

Serina Therapeutics Inc trading halted, volatility trading pause

2025-08-26T13:40:26.000Z - 10 months ago

Serina Therapeutics Inc trading halted, volatility trading pause

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway

Aug 25, 2025, 4:15 PM EDT - 10 months ago

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 11, 2025, 4:30 PM EDT - 10 months ago

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

Jul 29, 2025, 6:44 AM EDT - 11 months ago

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Jul 28, 2025, 6:00 AM EDT - 11 months ago

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

Jul 10, 2025, 4:10 PM EDT - 11 months ago

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

Jul 1, 2025, 4:15 PM EDT - 1 year ago

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

Jun 23, 2025, 7:24 PM EDT - 1 year ago

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Jun 17, 2025, 8:30 PM EDT - 1 year ago

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Jun 17, 2025, 6:00 AM EDT - 1 year ago

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

Jun 9, 2025, 4:05 PM EDT - 1 year ago

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

May 22, 2025, 4:50 PM EDT - 1 year ago

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

May 14, 2025, 3:15 PM EDT - 1 year ago

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 8, 2025, 4:23 PM EDT - 1 year ago

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Apr 29, 2025, 6:00 AM EDT - 1 year ago

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Apr 15, 2025, 6:30 AM EDT - 1 year ago

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

Apr 8, 2025, 4:30 PM EDT - 1 year ago

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Apr 7, 2025, 6:30 AM EDT - 1 year ago

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025, 4:30 PM EDT - 1 year ago

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Mar 24, 2025, 6:30 AM EDT - 1 year ago

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Feb 12, 2025, 4:15 PM EST - 1 year ago

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Feb 3, 2025, 4:30 PM EST - 1 year ago

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Jan 15, 2025, 4:05 PM EST - 1 year ago

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Jan 14, 2025, 5:25 PM EST - 1 year ago

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Dec 16, 2024, 6:00 AM EST - 1 year ago

Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

Dec 11, 2024, 6:05 AM EST - 1 year ago

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Dec 2, 2024, 5:22 PM EST - 1 year ago

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 12, 2024, 5:00 PM EST - 1 year ago

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 6:42 PM EDT - 1 year ago

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Aug 9, 2024, 4:15 PM EDT - 1 year ago

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

Jul 29, 2024, 8:30 AM EDT - 2 years ago

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation

Jul 18, 2024, 5:00 PM EDT - 2 years ago

Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation

Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

May 14, 2024, 4:05 PM EDT - 2 years ago

Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

robiein35
robiein35 Jun. 1 at 11:40 PM
$SER Accumulate and hold for 6 months for + or - 100%. Serina expects to advance to the next cohort following a blinded safety review in the third quarter of 2026, with topline data from the study anticipated in the first half of 2027.
1 · Reply
gamgee11
gamgee11 May. 24 at 5:52 PM
$SER
0 · Reply
dthekang
dthekang May. 22 at 3:12 PM
$SER anyone?
0 · Reply
dthekang
dthekang May. 20 at 9:51 AM
$SER anybody here?
0 · Reply
dthekang
dthekang May. 14 at 2:05 PM
$SER cmon…
0 · Reply
SuperGreenToday
SuperGreenToday May. 12 at 12:44 PM
$SER
0 · Reply
MauriceMauriceMaurice
MauriceMauriceMaurice May. 11 at 10:24 PM
$SMMT $EGG $SER
0 · Reply
Monogg
Monogg May. 5 at 10:35 PM
$SER These are scammers—they’ve approved another dilution up to 2 million shares, with the first step being 125,000. Be careful! Do not buy shares of these fraudsters.
0 · Reply
dthekang
dthekang May. 4 at 6:53 PM
$SER
0 · Reply
gmc109
gmc109 Apr. 27 at 4:15 PM
$SER in few days to 4$?
0 · Reply
KaShing01
KaShing01 Apr. 27 at 2:35 PM
$SER
0 · Reply
dthekang
dthekang Apr. 17 at 1:42 PM
$SER what the farks goin on here eh?
0 · Reply
focafoca99
focafoca99 Apr. 7 at 9:08 PM
$SER is promoting a summit presentation on POZ-based lipid nanoparticles and ionizable lipids.
0 · Reply
Eliza1
Eliza1 Apr. 7 at 4:13 PM
$SER a PR after the presentation would give this stock a boost. Obviously, they have something positive to say.
1 · Reply
Eliza1
Eliza1 Apr. 7 at 1:28 PM
$SER https://finance.yahoo.com/sectors/healthcare/articles/serina-therapeutics-present-5th-lnp-100000383.html
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:30 PM
$SER says NYSE American accepted its compliance plan, which removes the immediate listing overhang but leaves execution to prove out.
0 · Reply
Eliza1
Eliza1 Apr. 2 at 11:41 PM
$SWMR $EVTV $SER all could go much higher Monday.
0 · Reply
Eliza1
Eliza1 Apr. 2 at 9:16 PM
$SER hmmm , perhaps with this news this stock can head up to 4 or 5 on Monday.
0 · Reply
gamgee11
gamgee11 Apr. 2 at 8:17 PM
$SER nice green
0 · Reply
Eliza1
Eliza1 Apr. 1 at 11:57 PM
$SER like $CYCN, OPEN AT $4 +
0 · Reply
Eliza1
Eliza1 Mar. 31 at 6:16 PM
$EVTV $COMP IS UP 3%! the small caps will follow-trade accordingly which means cover your shorts now-$SER $SWMR are all included at the very least.
0 · Reply